1-20 of 23
insulin glargine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)

Steven Edelman, Jennifer Goldman, Daniel C. Malone, Ronald Preblick, Kovida Munaga, Xuan Li, Jasvinder Gill, Sumana Gangi
Journal: Clinical Diabetes
Clin Diabetes 2023;41(3):425–434
https://doi.org/10.2337/cd22-0096
Published: 28 March 2023
View article titled, Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
Open the PDF for Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100) in another window
Journal Articles

Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes

Simon Heller, João Filipe Raposo, Santiago Tofé, Wasim Hanif, Zbynek Schroner, Su Down, Thomas Blevins
Journal: Clinical Diabetes
Clin Diabetes 2023;41(2):154–162
https://doi.org/10.2337/cd22-0016
Published: 09 August 2022
View article titled, Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
Open the PDF for Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes in another window
Journal Articles

A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications

Paulo H.R.F. Almeida, Brian Godman, Vania dos Santos Nunes-Nogueira, Lívia L.P. de Lemos, Francisco de Assis Acúrcio, Augusto A. Guerra-Junior, Vânia E. de Araújo, Alessandra M. Almeida, Juliana Alvares-Teodoro
Journal: Clinical Diabetes
Clin Diabetes 2022;40(3):312–326
https://doi.org/10.2337/cd21-0068
Published: 01 July 2022
View article titled, A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications
Open the PDF for A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications in another window
Journal Articles

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?

Michelle A. Crisher, Christopher A. Giuliano, Carrie L. Hartner
Journal: Clinical Diabetes
Clin Diabetes 2019;37(2):167–171
https://doi.org/10.2337/cd18-0065
Published: 01 April 2019
View article titled, Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
Open the PDF for Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ? in another window
Journal Articles

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial

Louis Chaykin, Anuj Bhargava, Raymond de la Rosa, Carol H. Wysham, Lone Nørgård Troelsen, Signe H. Østoft, Athena Philis-Tsimikas
Journal: Clinical Diabetes
Clin Diabetes 2019;37(1):73–81
https://doi.org/10.2337/cd18-0016
Published: 01 January 2019
View article titled, Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
Open the PDF for Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial in another window
Includes: Supplementary data
Journal Articles

Timely News and Notes for Primary Care Providers from the American Diabetes Association

Max Bingham, PhD
Journal: Clinical Diabetes
Clin Diabetes 2018;36(4):276–280
https://doi.org/10.2337/cd18-0072
Published: 01 October 2018
View article titled, Timely News and Notes for Primary Care Providers from the American Diabetes Association
Open the PDF for Timely News and Notes for Primary Care Providers from the American Diabetes Association in another window
Journal Articles

Basaglar: A Hypersensitivity Reaction

Elizabeth M. Gavioli, Roman Fazylov, Gulmira Sardo
Journal: Clinical Diabetes
Clin Diabetes 2018;36(2):205–207
https://doi.org/10.2337/cd17-0051
Published: 01 April 2018
View article titled, Basaglar: A Hypersensitivity Reaction
Open the PDF for Basaglar: A Hypersensitivity Reaction in another window
Journal Articles

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know

Neil Skolnik, Debbie Hinnen, Yan Kiriakov, Melissa L. Magwire, John R. White, Jr.
Journal: Clinical Diabetes
Clin Diabetes 2018;36(2):174–182
https://doi.org/10.2337/cd17-0048
Published: 01 April 2018
View article titled, Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
Open the PDF for Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know in another window
Journal Articles

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

Vanita R. Aroda, Joseph R. Arulandu, Anthony J. Cannon
Journal: Clinical Diabetes
Clin Diabetes 2018;36(2):138–147
https://doi.org/10.2337/cd17-0065
Published: 01 April 2018
View article titled, Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
Open the PDF for Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One? in another window
Journal Articles

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications

Carol H. Wysham, Carlos Campos, Davida Kruger
Journal: Clinical Diabetes
Clin Diabetes 2018;36(2):149–159
https://doi.org/10.2337/cd17-0064
Published: 01 April 2018
View article titled, Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications
Open the PDF for Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications in another window
Journal Articles

Fixed-Ratio Combinations

Emmeline Tran
Journal: Clinical Diabetes
Clin Diabetes 2017;35(4):242–246
https://doi.org/10.2337/cd17-0037
Published: 01 October 2017
View article titled, Fixed-Ratio Combinations
Open the PDF for Fixed-Ratio Combinations in another window
Journal Articles

I Am Not a Diabetic

Stephen Brunton
Journal: Clinical Diabetes
Clin Diabetes 2017;35(3):125
https://doi.org/10.2337/cd17-0034
Published: 01 July 2017
View article titled, I Am Not a Diabetic
Open the PDF for I Am Not a Diabetic in another window
Journal Articles

Basaglar

Cheyenne Newsome
Journal: Clinical Diabetes
Clin Diabetes 2017;35(3):181
https://doi.org/10.2337/cd017-0025
Published: 01 July 2017
View article titled, Basaglar
Open the PDF for Basaglar in another window
Journal Articles

Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin

Mark L. Warren, Louis B. Chaykin, Serge Jabbour, Mae Sheikh-Ali, Charlotte T. Hansen, Thor S.S. Nielsen, Paul Norwood
Journal: Clinical Diabetes
Clin Diabetes 2017;35(2):90–95
https://doi.org/10.2337/cd15-0058
Published: 01 April 2017
View article titled, Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin
Open the PDF for Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin in another window
Journal Articles

Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes

John R. White, Jr.
Journal: Clinical Diabetes
Clin Diabetes 2016;34(2):86–91
https://doi.org/10.2337/diaclin.34.2.86
Published: 01 April 2016
View article titled, Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes
Open the PDF for Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes in another window
Journal Articles

Clinical Considerations for Insulin Pharmacotherapy in Ambulatory Care, Part Two: Review of Primary Literature and an Evidence-Based Approach for Treatment

Maria Miller Thurston, John A. Galdo, Catherine A. Bourg
Journal: Clinical Diabetes
Clin Diabetes 2015;33(1):20–27
https://doi.org/10.2337/diaclin.33.1.20
Published: 01 January 2015
View article titled, Clinical Considerations for Insulin Pharmacotherapy in Ambulatory Care, Part Two: Review of Primary Literature and an Evidence-Based Approach for Treatment
Open the PDF for Clinical Considerations for Insulin Pharmacotherapy in Ambulatory Care, Part Two: Review of Primary Literature and an Evidence-Based Approach for Treatment in another window
Includes: Supplementary data
Journal Articles

A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes

Dawn Battise, PharmD
Journal: Clinical Diabetes
Clin Diabetes 2013;31(4):166–170
https://doi.org/10.2337/diaclin.31.4.166
Published: 01 October 2013
View article titled, A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes
Open the PDF for A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes in another window
Journal Articles

Blood Glucose Monitoring and Underlying Question of Hypoglycemia Are Both Essential to Preventing Hypoglycemia in Nursing Home Residents

Joyce A. Lekarcyk, BA, RN, CDE, Linda Himmel, MSN, FNP-BC, CDE, DCC, Medha Munshi, MD
Journal: Clinical Diabetes
Clin Diabetes 2013;31(1):28–30
https://doi.org/10.2337/diaclin.31.1.28
Published: 01 January 2013
View article titled, Blood Glucose Monitoring and Underlying Question of Hypoglycemia Are Both Essential to Preventing Hypoglycemia in Nursing Home Residents
Open the PDF for Blood Glucose Monitoring and Underlying Question of Hypoglycemia Are Both Essential to Preventing Hypoglycemia in Nursing Home Residents in another window
Journal Articles

A Unique Case of Basal-Bolus Therapy

Jessica K. Devin, MD, Michael J. Fowler, MD
Journal: Clinical Diabetes
Clin Diabetes 2006;24(4):187–189
https://doi.org/10.2337/diaclin.24.4.187
Published: 01 October 2006
View article titled, A Unique Case of Basal-Bolus Therapy
Open the PDF for A Unique Case of Basal-Bolus Therapy in another window
Journal Articles

Treating New-Onset Catabolic Type 2 Diabetes With Glargine and Lispro

Dawn E. DeWitt, MD, MSc, FACP, FRACP
Journal: Clinical Diabetes
Clin Diabetes 2006;24(4):180–181
https://doi.org/10.2337/diaclin.24.4.180
Published: 01 October 2006
View article titled, Treating New-Onset Catabolic Type 2 Diabetes With Glargine and Lispro
Open the PDF for Treating New-Onset Catabolic Type 2 Diabetes With Glargine and Lispro in another window